Sera PrognosticsDecember 9, 2024Sera Prognostics to Present PRIME Study Results at 2025 SMFM Pregnancy Meeting
Sera PrognosticsJuly 1, 2024Sera Prognostics Added to Russell 2000 and 3000 Indexes Following Conclusion of 2024 Indexes Annual Reconstitution
Sera PrognosticsDecember 6, 2023Sera Prognostics Announces Primary Endpoint Criteria Met in Pivotal Prime Study Interim Look – Enrollment to Stop Due to Success
Sera PrognosticsMay 15, 2023Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO
Sera PrognosticsFebruary 15, 2023Sera Prognostics Announces Positive Top-line Data from AVERT PRETERM TRIAL
Sera PrognosticsNovember 15, 2022Sera Prognostics Announces Publication of Data Predicting Clinical Utility and Cost Effectiveness of the PRETRM® Test-and-Treat Strategy Across Diverse Populations
Sera PrognosticsSeptember 22, 2022Banner Health, Sera Prognosics Team Up to Provide PreTRM® Test to Cover Pregnant Members
Sera PrognosticsMay 20, 2022Sera Prognostics Presents Data Demonstrating the Health & Economic Benefit of PRETRM® Testing at Ispor Annual Meeting
Sera PrognosticsMay 5, 2022Sera Prognostics and Newborn Foundation Partner to Reduce Risks Associated with Preterm Birth and Improve Health Equity Through the “Every Mother, Every Baby” Project
Sera PrognosticsMarch 18, 2022Sera Prognostics Presents Data Demonstrating Prediction of Preeclampsia Utilizing Protein Biomarker and Clinical Factors at SRI Annual Meeting
